EUVIMEDEUVIMED entdecken
Crossref

Clinical Profiles of Leucine-Rich Alpha-2 Glycoprotein for Indicating Mucosal Healing in Ulcerative Colitis Patients under Administration of Molecular-Targeted Drug

Satohiro Matsumoto, Hirosato Mashima

Digestive Diseases · 2024

DOI: 10.1159/000542062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases, 2024. Verfasst von Satohiro Matsumoto und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Jichi Medical University Saitama Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Glycoproteins, Intestinal Mucosa, Molecular Targeted Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Leucine-rich alpha-2 glycoprotein (LRG) is a useful serum biomarker for monitoring disease activity during remission in ulcerative colitis (UC). Because LRG levels differ among patients, it is necessary to assess them after profiling patients, especially in patients with refractory UC undergoing treatment with molecular-targeted drugs. This study aimed to analyze LRG levels that indicate mucosal healing according to clinical characteristics and molecular-targeted drugs.

Methods

Among 214 patients with UC treated with biologics or Janus kinase (JAK) inhibitors, this study evaluated 111 patients (174 measurements) who achieved mucosal healing based on colonoscopy performed within 2 months before and after LRG measurement and experienced no changes in disease status or treatment during the same period. We analyzed the relationship of LRG with clinical characteristics (including sex, age, body mass index, and disease type and duration) and molecular-targeted drugs.

Results

Compared with men, women had significantly higher LRG levels (9.5 μg/mL vs. 11.3 μg/mL, p < 0.001). In addition, LRG levels were significantly higher in older patients (12.0 μg/mL vs. 9.8 μg/mL, p < 0.01). LRG levels were the highest in patients treated with vedolizumab and lower in patients treated with JAK inhibitors (vedolizumab: 12.7 μg/mL; tofacitinib: 8.9 μg/mL; upadacitinib: 8.5 μg/mL; and filgotinib: 9.1 μg/mL; p < 0.0001).

Conclusion

Among the patients who achieved mucosal healing, LRG levels were significantly higher in women and older patients. LRG levels differed according to the molecular-targeted drug used and were higher with vedolizumab and lower with JAK inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeGlycoproteinsIntestinal MucosaMolecular Targeted TherapyHumansMaleFemaleMiddle AgedAdultBiomarkersAgedJanus Kinase InhibitorsYoung AdultAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

BiologicsJanus kinase inhibitorsLeucine-rich alpha-2 glycoproteinMolecular-targeted drugMucosal healingUlcerative colitis

Substanzen

GlycoproteinsLRG1 protein, humanBiomarkersJanus Kinase InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Gastroenterology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Zitieren

APA

Matsumoto, S., & Mashima, H. (2024). Clinical Profiles of Leucine-Rich Alpha-2 Glycoprotein for Indicating Mucosal Healing in Ulcerative Colitis Patients under Administration of Molecular-Targeted Drug. Digestive Diseases. https://doi.org/10.1159/000542062

Vancouver

Matsumoto S, Mashima H. Clinical Profiles of Leucine-Rich Alpha-2 Glycoprotein for Indicating Mucosal Healing in Ulcerative Colitis Patients under Administration of Molecular-Targeted Drug. Digestive Diseases. 2024. doi:10.1159/000542062

BibTeX
@article{Matsumoto2024,
  author = {Matsumoto, Satohiro and Mashima, Hirosato},
  title = {Clinical Profiles of Leucine-Rich Alpha-2 Glycoprotein for Indicating Mucosal Healing in Ulcerative Colitis Patients under Administration of Molecular-Targeted Drug},
  journal = {Digestive Diseases},
  year = {2024},
  doi = {10.1159/000542062}
}
Kostenlos starten →